A Phase 1, Dose Escalation Study of Flotetuzumab, a CD123 x CD3 DART Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia.
- Wei, Andrew (Primary Chief Investigator (PCI))
- Kennedy, Nola (Project Manager)
Project: Research